A critical evaluation of crizanlizumab for the treatment of sickle cell disease

Karki, Nabin Raj; Saunders, Katherine; Kutlar, Abdullah

doi:10.1080/17474086.2022.2023007

Cited by 9 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Crizanlizumab, a human monoclonal antibody targeting P-selectin, is approved for use in patients with sickle cell disease 184 . Crizanlizumab decreases the frequency of vaso-occlusive crisis in these patients and has a good safety profile across several studies and 1,545 patient-years of treatment 185 . Importantly, no increased risk of infection was reported, which might have been expected because platelets, as discussed earlier in this article, facilitate the migration of leukocytes to fight pathogens.…”

Section: Therapeutic Targeting Of Plateletsmentioning

confidence: 99%

The role of platelets in immune-mediated inflammatory diseases

et al. 2023

View full text Add to dashboard Cite

Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive and uncontrolled inflammation and thrombosis, both of which are responsible for organ damage, morbidity and death. Platelets have long been known for their role in primary haemostasis, but they are now also considered to be components of the immune system and to have a central role in the pathogenesis of IMIDs. In patients with IMIDs, platelets are activated by disease-specific factors, and their activation often reflects disease activity. Here we summarize the evidence showing that activated platelets have an active role in the pathogenesis and the progression of IMIDs. Activated platelets produce soluble factors and directly interact with immune cells, thereby promoting an inflammatory phenotype. Furthermore, platelets participate in tissue injury and promote abnormal tissue healing, leading to fibrosis. Targeting platelet activation and targeting the interaction of platelets with the immune system are novel and promising therapeutic strategies in IMIDs.

show abstract

Section: Therapeutic Targeting Of Plateletsmentioning

confidence: 99%

The role of platelets in immune-mediated inflammatory diseases

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is a drug used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia which was recently FDA approved in 2019. The patient did report complete relief in the occurences of vaso-occlusive crises when on the drug but became non-compliant in therapy later [6].…”

Section: Discussionmentioning

confidence: 89%

Sickle cell disease - Impact of delayed diagnosis and non compliance to treatment

Sharma¹

2023

J Clin Images Med Case Rep

View full text Add to dashboard Cite

show abstract

“…Reduce the burden of sickled cells [94,95] Hydroxyurea Increase fetal hemoglobin (HbF) to stop polymers forming in the sickle hemoglobin [96] Hematopoietic stem cell transplantation Reverse the sickle phenotype [97,98] L-glutamine Antioxidant effects [99] Hemoglobin S (HbS) polymerization inhibitors Prevent HbS polymerization [100] Monoclonal antibody (crizanlizumab) Reduce selectin-mediated adhesion [101] Gene editing therapy (Casgevy™) Editing faulty gene in a patient's bone marrow stem cells [102] Recent Advanced Therapeutic Approaches for Sickle Cell Disease…”

Section: Blood Transfusionmentioning

confidence: 99%

Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions

Bell,

Varzakas,

Psaltopoulou

et al. 2024

Nutrients

View full text Add to dashboard Cite

Sickle cell disease (SCD), a distinctive and often overlooked illness in the 21st century, is a congenital blood disorder characterized by considerable phenotypic diversity. It comprises a group of disorders, with sickle cell anemia (SCA) being the most prevalent and serious genotype. Although there have been some systematic reviews of global data, worldwide statistics regarding SCD prevalence, morbidity, and mortality remain scarce. In developed countries with a lower number of sickle cell patients, cutting-edge technologies have led to the development of new treatments. However, in developing settings where sickle cell disease (SCD) is more prevalent, medical management, rather than a cure, still relies on the use of hydroxyurea, blood transfusions, and analgesics. This is a disease that affects red blood cells, consequently affecting most organs in diverse manners. We discuss its etiology and the advent of new technologies, but the aim of this study is to understand the various types of nutrition-related studies involving individuals suffering from SCD, particularly in Africa. The interplay of the environment, food, gut microbiota, along with their respective genomes collectively known as the gut microbiome, and host metabolism is responsible for mediating host metabolic phenotypes and modulating gut microbiota. In addition, it serves the purpose of providing essential nutrients. Moreover, it engages in direct interactions with host homeostasis and the immune system, as well as indirect interactions via metabolites. Nutrition interventions and nutritional care are mechanisms for addressing increased nutrient expenditures and are important aspects of supportive management for patients with SCD. Underprivileged areas in Sub-Saharan Africa should be accompanied by efforts to define and promote of the nutritional aspects of SCD. Their importance is key to maintaining well-being and quality of life, especially because new technologies and products remain limited, while the use of native medicinal plant resources is acknowledged.

show abstract

A critical evaluation of crizanlizumab for the treatment of sickle cell disease

Cited by 9 publications

References 57 publications

The role of platelets in immune-mediated inflammatory diseases

The role of platelets in immune-mediated inflammatory diseases

Sickle cell disease - Impact of delayed diagnosis and non compliance to treatment

Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions

Contact Info

Product

Resources

About